Savara Inc (NASDAQ:SVRA - Get Free Report)'s share price traded down 3.2% during trading on Friday . The stock traded as low as $3.34 and last traded at $3.36. 61,820 shares were traded during mid-day trading, a decline of 95% from the average session volume of 1,250,333 shares. The stock had previously closed at $3.47.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on the company. Evercore ISI reissued an "in-line" rating and set a $5.00 price target (down from $7.00) on shares of Savara in a research note on Wednesday, November 13th. JMP Securities reissued a "market outperform" rating and set a $9.00 target price on shares of Savara in a report on Tuesday, October 1st. Finally, HC Wainwright decreased their price target on shares of Savara from $10.00 to $6.00 and set a "buy" rating for the company in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Savara currently has a consensus rating of "Moderate Buy" and a consensus price target of $10.17.
View Our Latest Stock Report on SVRA
Savara Stock Performance
The stock's 50 day moving average price is $3.66 and its 200 day moving average price is $4.08. The company has a market capitalization of $576.64 million, a P/E ratio of -7.81 and a beta of 1.02. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70.
Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.11). As a group, equities analysts expect that Savara Inc will post -0.45 EPS for the current year.
Insiders Place Their Bets
In related news, Director Joseph S. Mccracken acquired 20,000 shares of the business's stock in a transaction dated Tuesday, November 19th. The shares were bought at an average price of $2.95 per share, with a total value of $59,000.00. Following the transaction, the director now directly owns 210,837 shares of the company's stock, valued at $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.13% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Savara
A number of large investors have recently modified their holdings of the company. Virtu Financial LLC bought a new stake in shares of Savara during the third quarter worth about $67,000. Barclays PLC boosted its stake in Savara by 217.5% during the 3rd quarter. Barclays PLC now owns 231,005 shares of the company's stock valued at $979,000 after purchasing an additional 158,244 shares during the last quarter. Teachers Retirement System of The State of Kentucky increased its holdings in Savara by 148.0% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 132,425 shares of the company's stock worth $561,000 after purchasing an additional 79,022 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Savara by 10.8% in the third quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company's stock worth $11,564,000 after purchasing an additional 264,825 shares during the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of Savara by 22.9% in the third quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company's stock valued at $36,566,000 after purchasing an additional 1,608,522 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors.
About Savara
(
Get Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Further Reading
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
